The biologic tocilizumab and the JAK inhibitor tofacitinib can increase lipids in RA patients, a meta-analysis shows. Compared with placebo tocilizumab and tofacitinib moderately increased levels of HDL, LDL and total cholesterol in RA patients. But the mechanism by which the drugs affect lipid levels is unclear. The long-term consequences for patients needed to be assessed.